The clinical presentation of the novel COVID-19 may vary from mild cases with fever, fatigue, and cough to moderate–severe cases involving pneumonia and multiorgan failure [10], and several factors may predispose COVID-19 patients to adverse outcomes. The older age, critical disease, and high levels of inflammatory markers have been associated with increased risk of death [11]. Patients with moderate to severe forms of COVID-19 normally require hospitalizations and pharmacological treatments. However, currently, there is no solid evidence that any potential drug improves outcomes in patients with suspected or confirmed COVID-19 [12,13]. Only clinical experience and treatment guidance based on repurposed and experimental treatments are available.